Silencing of gene expression by methylation of CpG islands in regulatory elements is frequently observed in cancer. However, an influence of the most common oncogenic signalling pathways onto DNA methylation has not yet been investigated thoroughly. To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126. Analysis of gene expression by microarray and Northern blot analysis revealed the MEK/ERK target genes clusterin, matrix metalloproteinase 2 (Mmp2), peptidylpropyl isomerase C-associated protein, syndecan 4, Timp2 and Thbs1 to be repressed in the HRAS-transformed FE-8 cells in a MEK/ ERK-and methylation-dependent manner. Hypermethylation of putative regulatory elements in HRAS-transformed cells as compared to immortalized fibroblasts was detected within a CpG island 14.5 kb upstream of clusterin, within the clusterin promoter and within a CpG island of the Mmp2 promoter by bisulphite sequencing. Furthermore, hypermethylation of the clusterin promoter was observed 10 days after induction of HRAS in immortalized rat fibroblasts and a clear correlation between reduced clusterin expression and hypermethlyation could also be observed in distinct rat tissues. These results suggest that silencing of individual genes by DNA methylation is controlled by oncogenic signalling pathways, yet the mechanisms responsible for initial target gene suppression are variable.
Introduction
Activation of RAS proteins by point mutations is frequently observed in cancers of the colon, pancreas, thyroid, lung and the myeloid system (Bos, 1989) . RAS genes encode small GTP-binding proteins that act as major molecular switches in signal transduction processes, transmitting extracellular signals to cytoplasmic signalling cascades . The oncogenic forms of RAS proteins are locked in their active state and contribute to transformation, angiogenesis, invasion and metastasis by constitutive activation of downstream pathways. Among these are the RAF/ MEK/ERK (MAPK) cascade of cytoplasmic kinases (Mansour et al., 1994) , the phosphoinositide 3-phosphate lipid kinases (Downward, 1998) , the small GTPbinding proteins RAC and RHO (Zohn et al., 1998) and the family of guanine nucleotide exchange factors (RalGDS, RGL and Rlf/RGL2) that serve as activators of the small GTPases RalA and RalB (Wolthuis and Bos, 1999) .
RAS signalling is linked to the activation of transcription factors of the AP-1 and Ets families, and also to NF-kB, SRF and c-Myc, all of which induce a complex set of transcriptional targets. Meanwhile, a number of RAS-dependent gene expression profiles have confirmed the quantitative and qualitative impact of RAS signalling on gene expression control (Zuber et al., 2000; Brem et al., 2001; Gadal et al., 2003; Fensterer et al., 2004; Tchernitsa et al., 2004) . These studies revealed that similar numbers of genes are activated and repressed by RAS oncogenes and suggested that RAS can influence the expression of defined groups of genes in a signalling pathway-dependent manner (Tchernitsa et al., 2004) . Transcriptional activation of critical RAS target genes involved in cell cycle control, mitogenic signalling or metastasis has been studied in much detail. In contrast, the mechanisms of RAS-dependent gene repression have been unfolded only for a few individual genes. A recent example of RAS-dependent gene repression is the observed transcriptional block onto the thrombospondin 1 gene (THBS1), which is repressed in a RAS/PI-3K/RHO-and ROCK-dependent manner through a phosphorylated c-myc protein (Watnick et al., 2003) . The Ets-2 protein is a member of the ETS family of transcription factors directly activated by mitogen-activated protein kinases and functionally involved in the activation of RAS target genes. However, Ets-2 can inhibit BRCA-1 transcription through recruitment of components of the SWI/SNF repressive chromatin-remodelling complex Wei et al., 2003) . Furthermore, HDAC4, which is a member of the histone deacetylase family, was shown to translocate into the nucleus in cells transfected with oncogenic RAS (Zhou et al., 2000) . These observations indicate that RAS-dependent signalling pathways alter DNA-protein interactions at regulatory elements by stimulating the recruitment of components determining DNA structure. Also, increased expression of DNMT1 has been detected in tumour cells (Kautiainen and Jones, 1986; Issa et al., 1993) . Stable expression of HRAS(G12V) induces transcription of DNMT1 via an AP-1 site in the promoter region (Rouleau et al., 1995) , and elevated DNMT1 levels were correlated with the 5-methylcytosine content and demonstrated to be a prerequisite for fos-mediated transformation (Bakin and Curran, 1999) . Recently, a set of genes was identified that was commonly downregulated in rat fibroblasts transformed by c-fos, v-fos, Hras(G12V) or Dnmt1 (Ordway et al., 2004) suggesting a close connection between RAS transformation and epigenetic gene regulation.
In the current manuscript, we investigated the impact of constitutive RAS activation on DNA methylation of putative regulatory elements by correlating gene expression data with bisulphite sequencing data. We identified a set of MEK/ERK target genes downregulated in FE-8 cells and re-expressed after treatment with 5-Aza-2-deoxycytidine (5-Aza-CdR) and after treatment with the MEK1,2 inhibitor U0126. The clusterin gene revealed suppression due to hypermethylation of regulatory regions in cells transformed stably or inducibly by activated HRAS, suggesting that oncogenic signalling can directly influence DNA methylation.
Results

5-Aza-CdR and Trichostatin A cause growth inhibition and cell death in immortalized and HRAS-transformed fibroblasts
We investigated the effects of the demethylating agent 5-Aza-CdR and the HDAC1 inhibitor trichostatin A (TSA) on growth and viability of immortalized 208F rat fibroblasts and the HRAS-transformed derivative FE-8. A dose-dependent inhibition of cell growth was observed for both cell lines after treatment with 0.1-10 mM 5-Aza-CdR for 96 h and with 5-50 ng/ml TSA for 72 h (Figure 1a) . Concentrations above 1 mM 5-Aza-CdR and 25 ng/ml TSA caused growth inhibition owing to cytotoxic effects as indicated by an increase in cell death (Figure 1b) . For further experiments, we selected concentrations between 0.1 and 0.3 mM 5-Aza-CdR and between 5 and 25 ng/ml TSA allowing for DNA replication and proliferation, excluding cytotoxic effects. Western blot analysis demonstrated histone H3 hyperacetylation after TSA treatment, whereas the U0126-induced inhibition of MEK1,2 reduced the level of p44/ 42 ERK phosphorylation. Total DNMT1 protein levels were identical in the two cell lines and were also not affected by treatment with U0126 ( Figure 1c) .
A distinct set of genes downregulated in FE-8 cells is concordantly upregulated after treatment with 5-Aza-CdR as well as with U0126 Silencing of genes by methylation, particularly with regard to tumour suppressor genes, is frequently described in cancer cells and tumour samples. However, the mechanisms and signalling pathways involved in genespecific methylation are largely unknown. Therefore, we tested the hypothesis that methylation is involved in the downregulation of genes suppressed in a MEK/ERKdependent manner in HRAS(G12V)-transformed FE-8 cells.
First we investigated the expression of 73 RAS target genes previously shown to be suppressed in FE-8 cells by Northern blot analysis (Zuber et al., 2000) . Eighteen of these genes are regulated in a MEK/ERK-dependent and 55 genes are regulated in a MEK/ERK-independent manner. Treatment with 0.1 mM 5-Aza-CdR revealed a 5-Aza-CdR-dependent upregulation of 10 of the 18 MEK/ERK target genes (Table 1 ). In addition, 31 of 55 MEK/ERK-independent genes downregulated in FE-8 cells are upregulated after treatment with 5-Aza-CdR, suggesting that alternative RAS-dependent pathways influence the methylation of genes (data not shown).
To gain further access to candidate genes silenced by methylation in response to oncogenic signalling pathways, we hybridized cDNA probes derived from untreated and 5-Aza-CdR-treated 208F and FE-8 cells to an Affymetrix rat U34A oligonucleotide microarray. After treatment of 208F cells with 0.3 mM 5-Aza-CdR for 96 h, 108 genes (9%) were significantly upregulated and 169 genes (13%) were significantly downregulated. In FE-8 cells, 115 genes (8%) were significantly upregulated after treatment with 5-Aza-CdR and 216 genes (15%) were significantly downregulated. Thus, the overall number of genes deregulated after treatment with 5-Aza-CdR is not related to the RAS status of the cells. Further analysis identified 16 genes significantly lower expressed in untreated FE-8 cells compared to untreated 208F cells but upregulated after treatment with 5-Aza-CdR, exclusively in FE-8 cells (Table 2) . Within this set of genes silenced by a methylationdependent mechanism, syndecan 4, clusterin and Timp2 had earlier been demonstrated to be suppressed in a MEK/ERK-dependent manner in FE-8 cells (Zuber et al., 2000) and revealed a similar 5-Aza-CdR-mediated re-expression when analysed on Northern blots (Table 1) .
We verified the expression of six genes that were strongly induced after treatment with 5-Aza-CdR only in FE-8 cells. Clusterin, matrix metalloproteinase 2 (Figure 2 ). Combined treatment with 5-AzaCdR and TSA induced no further changes in gene expression compared to treatment with 5-Aza-CdR alone. It is also remarkable that Ppicap and Timp2, both located on chromosome 10q32.3 within a distance of 38 kb between the transcription start sites and no other coding regions in between, were induced by 5-AzaCdR and U0126, suggesting that the expression of genes within a certain chromosomal region may be subject to a common regulation.
Clusterin and matrix metalloproteinase 2 regulatory regions are methylated in HRAS-transformed cells We assumed that at least a subset of genes, upregulated in the HRAS(G12V)-transformed FE-8 cells after A recent publication suggested that Timp2 is silenced by promoter hypermethylation in invasive cervical carcinomas and in cervical cancer cell lines (Ivanova et al., 2004 ). However, the overall level of methylation within the CpG island of the Timp2 promoter was very low (Figure 3a) . Also, no significant differences in the methylation pattern within the CpG island of the syndecan 4 promoter were observed between 208F and FE-8 cells (Figure 3b ). In both genes, individual methylated CpGs were distributed randomly throughout the clones analysed ( Supplementary Figure 3a Within the clusterin promoter, no CpG island matching the criteria of Takai and Jones (2002) was found. Nevertheless, we analysed the clusterin promoter as hypomethylation of the clusterin promoter was described to be associated with high gene expression in rat testis and epididymis (Rosemblit and Chen, 1994) . Within the region comprising the entire exon 1, the overall level of methylation was low and no differences in the methylation frequency were observed between 208F and FE-8 cells (Figure 3c ). The picture changed upon investigation of the region ranging from À560 to À314 relative to the transcriptional start site. The methylation frequency of four out of six CpGs in FE-8 cells was significantly higher as compared to 208F cells (Figure 3d) . Overall, the methylation frequency for all six CpGs increased from 41% in 208F cells to 61% in FE-8 cells. Whereas only three of 20 clones (15%) analysed in 208F cells were at least methylated at five of six CpGs, this was true for 11 of 22 clones (50%) analysed in FE-8 cells. Strikingly, three CpGs hypermethylated in FE-8 cells are located in close proximity within a range of 11 nucleotides (region À385 to À376) in the clusterin promoter (Figure 3d) .
The only CpG island localized 5 0 of the clusterin promoter is found 14.5 kb upstream, with no coding sequences in between. This CpG island was hypermethylated in FE-8 cells compared to 208F cells within 28 of 30 CpGs investigated (Figure 3e ). Overall, 66% of all CpGs analysed in this specific location were methylated in FE-8 cells, whereas only 22% were methylated in 208F cells and at least 12 of 30 CpGs analysed were methylated in each clone of the FE-8 cells.
Within the Mmp2 gene, we analysed the methylation pattern of a fragment covering the sequence from À327 to À89 relative to the transcriptional start site harbouring a bona fide CpG island. The total methylation rate increased from 31% in 208F cells to 80% in FE-8 cells (Figure 3f ), where each clone was at least methylated at five of 11 positions.
Next, we investigated to which extent the hypermethylation observed at the presumed regulatory regions for clusterin and Mmp2 expression was altered after treatment with 0.1 mM 5-Aza-CdR in FE-8 cells. The clusterin promoter was completely demethylated after treatment with 5-Aza-CdR; only at the first 5 0 CpG, the methylation frequency was not reduced (Figure 4a ). In contrast, treatment with 0.1 mM 5-AzaCdR induced unequally distributed changes with regard to the methylation pattern of the clusterin CpG island (Figure 4b ). This was a surprising finding, which cannot be explained at the moment. Recently, a differential regulation of DNMT1, 3a and 3b in response to 5-AzaCdR treatment was reported (Schneider-Stock et al., 2005) , whether this also induces regional differences in DNA methylation has to be investigated in more detail.
At the Mmp2 promoter region, treatment with 5-AzaCdR induced an equally distributed, but incomplete demethylation in FE-8 cells (Figure 4c ). Interestingly, within the region harbouring the first five CpGs, the overall methylation frequency decreased from 89% in the untreated cells to 63% in the 5-Aza-CdR-treated FE8 cells. In nine of 32 5-Aza-CdR-treated clones, less than three CpGs were methylated, whereas methylation in the others was similiar to the untreated. Probably, a subpopulation of 5-Aza-CdR-treated cells is responsible for the increase of Mmp2 expression. In addition, we find that silencing of clusterin and Mmp2 is DNMT1 dependent, as inhibition of DNMT1 for 72 h by siRNA resulted in upregulation of clusterin and Mmp2 expression ( Figure 4d ).
As the clusterin promoter is largely demethylated after treatment with 5-Aza-CdR, we supposed that the methylation pattern of the clusterin promoter is crucial for clusterin expression. To rule out that the highlighted correlation between HRAS-mediated ERK activation and DNA hypermethylation occurred randomly in FE-8 cells, we investigated clusterin expression and clusterin promoter methylation in another HRAS-transformed cell line (FYJ10; Schwarte-Waldhoff et al., 1994) and in two phenotypically revertant cell lines (F4 and F9; Scha¨fer et al., 1998) . The revertants maintain a normal phenotype similar to their non-transformed precursors and exhibit low levels of ERK activation despite the continuous expression of the oncogene (Raudies et al., 2005) . As in FE-8 cells, clusterin is downregulated in the FYJ10 cells and upregulated after treatment with 5-Aza-CdR, U0126 and TSA, whereas the higher expression levels of clusterin in the revertants F4 and F9 cells are only slightly upregulated after TSA treatment (Figure 5a ). The reduction of clusterin expression correlates with methylation throughout the complete clusterin promoter in FYJ10 cells (overall methylation rate of 40%), whereas F4 and F9 cells show no methylation at all, except at the first CpG (Figure 5b ).
Long-term activation of HRAS establishes methylationmediated silencing, whereas short-term activation suppresses clusterin by histone deacetylation To analyse the impact of RAS signalling on Mmp2 and clusterin expression in a time-resolved manner, we analysed the regulation of these genes in IR-4 cells, which harbour an isopropyl-b-D-thiogalactoside (IPTG)-inducible HRAS (Liu et al., 1992; Sers et al., 2002) . IR-4 cells were derived from 208F immortalized rat fibroblast and display a similar immortalized phenotype. Upon induction of the HRAS oncogene, IR-4 cells transform and within 4 days adopt a phenotype similar to FE-8 cells (Sers et al., 2002) . Northern blot analysis revealed that 6-12 h after induction of HRAS in IR-4 cells, clusterin and Mmp2 mRNA levels begin to decline and are further downregulated until 72 h post induction (Figure 6a, upper panel) . Western blot analysis demonstrated that RAS protein levels in IR-4 cells increase slowly up to 6 h and are strongly enhanced from 12 to 72 h (Figure 6a, lower panel) . Then, we treated IR-4 cells simultaneously with IPTG to induce RAS and with either TSA (25 ng/ml) or 5-AzaCdR (0.1 mM; Figure 6b ). Demethylation or histone hyperacetylation disturbed the previously described morphological transformation of IR-4 cells within 72 h after HRAS induction (Sers et al., 2002) . Furthermore, TSA-induced histone hyperacetylation increased clusterin expression already 30 min after treatment and overrode the HRAS-induced repression of clusterin observed between 24 and 72 h (Figure 6b, right panel) , whereas the HRAS-induced repression of Mmp2 was not affected by treatment with TSA. These observations are in agreement with the effects observed in FE-8 cells and point to a clear difference in the mechanisms of initial Mmp2 and clusterin repression in response to HRAS. Treatment with 5-Aza-CdR neither affected downregulation of clusterin nor Mmp2 in IR-4 cells within 72 h (Figure 6b, left panel) .
To determine whether the HRAS-mediated hypermethylation of the clusterin promoter that we observed in FE-8 and FYJ10 cells is an immediate or delayed consequence of RAS activation, we treated IR-4 cells with IPTG up to 240 h. After treatment for 48 h, no differences in the methylation pattern compared to the untreated cells were observed, demonstrating that initial repression of clusterin expression is directly mediated by RAS activation, yet independent of promoter hypermethylation. However, 240 h after induction, the clusterin promoter was methylated at an overall rate of 35% (Figure 6c ). Among the 16 clones sequenced 10 days after RAS induction, 50% showed methylation only at the most 5 0 CpG; all other CpGs were unmethylated. The remaining clones exhibited a random distribution of CpG methylation (Supplementary Figure 6c) . Whether this indicates an allele-specific methylation of the clusterin promoter by oncogenic RAS remains to be investigated. 
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Expression of clusterin in normal rat tissues is inversely correlated with the methylation rate of the clusterin promoter and the clusterin CpG island In order to determine whether methylation of the clusterin promoter and of the clusterin CpG island also correlates with clusterin expression in normal rat tissues, we analysed clusterin expression in 17 tissue probes (Figure 7a ). Then, we selected three tissues exhibiting high (testis), intermediate (colon) and low (small intestine) clusterin expression for methylation studies. The clusterin promoter and the clusterin CpG island were nearly unmethylated in testis as expected from the high level of clusterin expression. The overall methylation of the clusterin promoter was 20% in colon and increased to a rate of 29% in small intestine. The overall methylation frequencies at the clusterin CpG island were at least twofold in colon and small intestine as compared to testis. These observations strengthen the hypothesis that silencing of clusterin is accompanied by hypermethylation within the clusterin promoter at an overall rate of 30%, similar to the rates observed in FYJ10 and IR-4 cells transformed by HRAS.
Discussion
DNA methylation is essential for the control of gene expression. In mammals, methylation serves several important biological purposes such as imprinting, control of gene expression during development and X-chromosome inactivation (Avner and Heard, 2001 ; Figure 7 High expression of clusterin in testis correlates with low clusterin promoter methylation and clusterin CpG island methylation. (a) Northern blot analysis for clusterin in several normal rat tissues. The RNA probes were arranged as follows: 1: lung; 2: brain; 3: brain (cerebellum); 4: heart; 5: breast; 6: small intestine (I); 7: skin; 8: stomach; 9: spleen; 10: liver; 11: kidney; 12: spleen; 13: muscle; 14: colon (C); 15: placenta; 16: liver; 17: testis (T). 18S rRNA hybridization served as a loading control. Comparative analysis of the methylation status within the (b) clusterin promoter and (c) clusterin CpG island in rat tissue from colon, small intestine and testis is shown. Comparison of per cent methylation for each individual CpG (numbered in 5 0 to 3 0 direction) in tissue of colon (black columns), small intestine (grey columns) and testis (white columns). The number of clones analysed for each cell line is indicated (n). . In addition, gene silencing by methylation is of particular importance in tumours, where DNA is often globally hypomethylated, but locally hypermethylated in CpGrich promoter regions of tumour suppressor genes such as p16
INK4a
, p15
INK4b , p14 ARF , p73, APC, or BRCA1 (Esteller et al., 2001; Esteller, 2003) .
The sequence of events resulting in gene-specific suppression owing to DNA methylation is still controversial (Esteller, 2002; Villar-Garea and Esteller, 2004) . A key epigenetic modification is methylation at histone H3 Lys9 (Lachner and Jenuwein, 2002) and in mammalian cells, DNMT3a was described in a complex with the methyltransferase SUV39H1. This demonstrates a connection between the enzymes responsible for DNA methylation and histone methylation (Fuks et al., 2003a) . Methyl-DNA-binding proteins, for example MeCP2, also associate with histone methyltransferases in vivo and recruit histone deacetylases to reinforce a repressive chromatin state (Fuks et al., 2003b) . Whether DNA methylation is a prerequisite for histone methylation or vice versa is currently unknown. In addition, a direct recruitment of DNMTs by transcription factors such as Myc (Brenner et al., 2005) or PML-RAR (Di Croce et al., 2002) can establish local changes in chromatin structure. Whereas the aforementioned mechanisms rather direct DNA methylating or histone methylating enzymes to specific regulatory regions, a third possibility to repress gene expression is the transcription factor-associated recruitment of histone deacetylases (Laduron et al., 2004) . This latter mechanism might govern the initial suppression of the clusterin gene in response to HRAS. Analysis of clusterin inhibition upon HRAS induction in IR-4 cells indicated that histone hypoacetylation is the primary event mediating inhibition of clusterin within the first 72 h. This primary suppression is likely to be mediated via the MEK/ERK signalling pathway, followed by promoter methylation 240 h after RAS induction. Thus, a potential interaction between HDAC1 and DNMT1 (Fuks et al., 2000) could then result in a further repression of gene expression by subsequent DNA methylation. A region from À426 to À311 is necessary for maximal clusterin promoter activity and deletion of this fragment decreased transcription of a reporter gene by up to 70% in rat Sertoli cells (Lymar et al., 2000) . Three CpGs detected as hypermethylated by bisulphite sequencing of the clusterin promoter are located at positions À385, À379 and À376 in close proximity to each other. The cytosines hypermethylated (underlined) reside within the sequence 5 0 -AACGTGGGCGTCGGG CGGTG-3 0 harbouring one Egr1 and two Sp1-binding sites. Most interestingly, induction of clusterin expression via MEK/ERK following ionizing radiation was recently shown to be dependent on the binding of Egr-1 to the promoter (Criswell et al., 2005) . These findings suggest that binding or activation of Egr1 and/or Sp1 are affected upon hypermethylation within the abovementioned area of the clusterin promoter.
Hypermethylation within the CpG island about 14.5 kb upstream of the clusterin gene was even more prominent in FE-8 cells than within the promoter region. Furthermore, analysis of clusterin expression in rat tissues revealed very low methylation of this CpG island in testis, supporting a role for this region in the control of clusterin expression. A splice variant of rat clusterin (Ensembl transcript ID: ENSRNOT000000 29806) with an alternative exon 1 is annotated approximately 1.5 kb downstream of the amplified region. Methylation of the CpG island might act as a switch for the induction of the alternative transcript. However, neither Northern blot analysis nor Reverse transcription-PCR using primers specific for the predicted exon 1 gave any hint for the existence of the alternative transcript (data not shown). Studies on the imprinted Igf2-H19-region in the mouse have already shown that long-range chromatin interactions contribute to the control of gene expression (Lopes et al., 2003) . Thus, we assume that this CpG island might regulate transcription of clusterin over a range of 14.5 kb in conjunction with the regulatory regions directly upstream of the transcriptional start.
In general, the overall methylation rates for clusterin increased by a rate of 20-40% in HRAS-transformed cell lines as compared to immortalized cell lines resulting in a strong downregulation. Similar effects were observed by Di Croce et al. (2002) for the RARb2 promoter, for example showing that RARb2 expression was silenced in NB4 cells at an overall methylation rate of 47%. After treatment with retinoid acid, the overall methylation rate decreased to 23%, which resulted in a re-expression of the RARb2 gene. This indicates that even moderate alterations in methylation might mediate profound changes in gene expression, an idea that was first suggested several years ago by Hsieh (1994) . Furthermore, alterations induced by continuous culturing might induce subtle changes in expression and methylation of individual genes, as obvious from the comparison of 208F, F9 and IR-4 cells. Therefore, the relevance of a certain methylation rate for the expression of an individual gene has to be investigated in several different sources.
In contrast to clusterin, Mmp2 could be subject to a direct, methylation-and histone deacetylation-independent but MEK/ERK-dependent inhibition first, followed by methylation of the CpG island. Whereas clusterin was suppressed in response to activated HRAS in different cell lines, Mmp2 exhibited a heterogeneous regulation via both HRAS-dependent and HRASindependent effects (data not shown). Therefore, it is currently unclear whether the observations made in FE-8 and IR-4 cells are of general importance for Mmp2 regulation.
Silencing of tumour suppressor genes by methylation clearly confers a selective advantage to the transformed cells, for example owing to the abrogation of cell cycle control; so what might be the role of clusterin and Mmp2 silencing in tumorigenesis? Clusterin is constitutively expressed in almost all mammalian tissues and is implicated in diverse physiological processes, including cell adhesion, tissue remodelling, membrane recycling, cell-cell interaction and apoptosis (reviewed by Jones and Jomary, 2002) . Opposing biological functions of clusterin have been described in distinct tumour types, which seem to be determined by different isoforms with cell type-specific modifications such as glycosylation and by alternative splicing of the human clusterin gene. Recent work suggested that only the secreted form of clusterin correlates with tumour progression, whereas the proapoptotic nuclear form, detected in normal tissue, decreases in expression in tumour cells (Leskov et al., 2003; Pucci et al., 2004) . Several findings support a role of clusterin as a potential tumour suppressor gene: clusterin induces p21-dependent apoptosis of colon and prostate carcinoma cells (Chen et al., 2004; Scaltriti et al., 2004b) . It is downregulated in low-and high-grade human prostate cancer (Scaltriti et al., 2004a) and in testicular germ cell tumours (Behrens et al., 2001) . Upregulation of clusterin leads to suppression of tumorigenesis in concert with the downregulation of HRAS (Kyprianou et al., 1991) . In RAS-transformed cell lines, clusterin expression is consistently downregulated (Klock et al., 1998; Tchernitsa et al., 2004) . Nevertheless, further experiments are required to investigate the contribution of clusterin suppression to RAS transformation and to investigate whether clusterin silencing is caused by promoter hypermethylation in tumour samples with mutated RAS.
Mmp2 belongs to the group of endopeptidases usually upregulated in cancer and their expression is associated with poor survival. Mice lacking Mmp2 develop fewer cancers than wild-type mice (Itoh et al., 1998) , but there is no linear relationship between Mmp2 expression level and the ability of cancer cell lines to invade matrigel (Deryugina et al., 1997) . Mmp2 is also involved in tumour angiogenesis; however, a selective role of different Mmps was demonstrated in the RIP-Tag2 insulinoma model (Bergers et al., 2000) . This suggests that the Mmp pattern of a given tumour cell is tightly controlled to provide the cell with angiogenic and invasive potential. Remarkably, Mmp2, Thbs1 and Timp2, all belonging to the same transcriptional module, functionally interact in tumorigenesis. Mmp2 is activated at the cell surface through a unique multistep pathway that involves Timp2 Deryugina et al., 2001) , and also THBS1, shown to be silenced by methylation in human cancers (Li et al., 1999) , has been reported to increase MMP2 activation (Taraboletti et al., 2000) . In contrast to Mmp2, two related genes Mmp3 and Mmp10 are upregulated in FE-8 and IR-4 cells and downregulated after inhibition of MEK1 by PD98059 (Zuber et al., 2000 and data not shown) . It is therefore likely that the MEK/ERK signalling pathway is responsible for a coordinated transcriptional regulation of Mmps and this might vary between individual cells such as FE-8 and FYJ10. The fact that no differences in the methylation pattern of the Timp2 region were observed is in line with the observations showing that Timp2 re-expression may be induced after treatment with the 5-Aza-CdR via an indirect mechanism involving the activation of NF-Y (Cappabianca et al., 2003) .
In summary, we investigated the impact of RAS oncogene activation on the methylation of candidate genes. We find that activation of an oncogenic signalling pathway can induce epigenetic modification to suppress gene expression directly as shown for clusterin and indirectly as suggested for Timp2 and syndecan 4. Future studies will aim to investigate the impact of distinct RAS-dependent signalling pathways on methylation of individual regulatory regions and to unravel the sequence of molecular events resulting in a persistent gene suppression following RAS activation.
Materials and methods
Cell culture conditions
Immortal rat 208F fibroblasts, the HRAS(G12V)-transformed derivatives FE-8 (Griegel et al., 1986) and FYJ10 (SchwarteWaldhoff et al., 1994) , and the revertant cell clones F4 and F9 (Scha¨fer et al., 1988) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2% penicillin-streptomycin, and 2 mM L-glutamine. IR-cells (clone IR-4) harbour an IPTG-inducible HRAS oncogene and were described earlier (Sers et al., 2002) . Expression of HRAS was induced by the addition of 20 mM isopropyl-1-thio-b-Dgalactoside. Stock solutions of 5-Aza-CdR (Sigma, St Louis, MO, USA) were prepared by dissolution at 10 mM in phosphate-buffered saline (pH 6.5). Trichostatin A (Sigma) was dissolved in ethanol (1 mg/ml) and U0126 (Promega, Madison, WI, USA) in dimethylsulphoxide (DMSO) (10 mM). Immediately before use, stock solutions were further diluted in medium. For demethylation experiments, cells were plated at a density of 1 Â 10 5 cells/100 mm dish and treated the next day. Medium and 5-Aza-CdR were changed every 24 h. For treatment with the HDAC inhibitor TSA and the MEK1, 2 inhibitor U0126, cells were plated at a density of 3 Â 10 5 cells/ 100 mm dish and treated the next day. Concentrations for treatments and time intervals were as indicated. Solvents were added to the controls in the appropriate concentration.
Cell growth was determined by seeding 5 Â 10 4 cells into a 60 mm dish followed by treatment the next day. At the time points indicated, cells were trypsinized, cell numbers determined using a haemacytometer and the fraction of living cells was calculated by Trypan blue exclusion (0.2% v/v).
Western blot analyses
Cells were solubilized in lysis buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% DOC, 1% NP-40, 0.1% SDS, complete protease inhibitor mix (Roche Diagnostics, Mannheim, Germany)) and 20 mg of the whole cell extracts was separated by SDS-polyacrylamide gel electrophoresis. After semi-dry blotting (BioRad, Hercules, CA, USA) to PVDF membranes (Hybond P, Amersham Pharmaceuticals, Buckinghamshire, UK), the membranes were blocked for 1 h in TBST (10 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween 20) with 5% non-fat dry milk and incubated with primary antibodies against RAS (Transduction Laboratories, Los Angeles, CA, USA), acetylhistone H3 (Lys9) (Cell Signaling), phospho-p44/42 MAPK (Thr202/Tyr204) (New England Biolabs, Ipswich, MA, USA), anti-DNMT1 (Alexis Biochemicals, San Diego, CA, USA), anti-a-tubulin (Chemicon, Temecula, CA, USA) and anti-bactin (Chemicon). Membranes were washed and incubated with peroxidase-conjugated secondary antibodies. Signals were detected by chemiluminescence reaction (ECL; Amersham Pharmaceuticals) according to the manufacturer's instructions.
Oligonucleotide microarray hybridizations
Total RNA was prepared from cultured cells using the TRIzol Reagent (Invitrogen) according to the manufacturer's instructions and dissolved in nuclease-free water. After isolation, RNA used for microarray hybridizations was purified by the RNeasy Mini Kit (Qiagen, Hilgen, Germany) and the RNA quality was determined on a LabChip Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). cDNA was synthesized from 5 mg of total RNA and synthesis of biotin-labelled cRNA was performed using the BioArray High Yield RNA transcription kit (Enzo Diagnostics, Farimigdale, NY, USA). cRNA was hybridized for 16 h at 451C to the Rat Genome oligonucleotide microarray U34A (Affymetrix, Santa Clara, CA, USA). Subsequent washing and staining of the arrays was performed using the GeneChip fluidics station protocol EukGE-WS2. Following washing and staining, the arrays were scanned using an Agilent G2500A GeneArray Scanner controlled by Microarray Suite 5.0 software (Affymetrix). The Data Mining Tool 3.0 (Affymetrix) and GeneSpring software package 6.1 (Silicon Genetics, Redwood City, CA, USA) were used to average results from different replicates and to perform statistical analysis. Experiments were performed in duplicate for each treatment and cell line, and only genes with a maximal deviation of fold change of o1.5 between the replicates and with a statistically significant t-test were further analysed. Genes with signal intensities below the background threshold in either control or 5-Aza-CdR-treated cells were regarded as background and excluded from analysis. All raw fluorescence intensity data and microarray image files are deposited within the public repository for microarray-based gene expression data ArrayExpress (http://www. ncbi.nlm.nih.gov/geo/), complying with minimum information about a microarray experiment (MIAME) and microarray gene expression database (MGED) group standards (Brazma et al., 2001) . The gene expression Omnibus accession number is GSE4427.
Northern blot analysis
Ten micrograms of RNA were denatured for 5 min at 951C and run on a 0.8% agarose/0.6 M formaldehyde gel for 4 h. The RNA was transferred to a nylon membrane (Nytran N, Schleicher & Schuell) and crosslinked by UV light. Membranes were pre-hybridized for 1 h at 661C in hybridization buffer (ExpressHyb, Clontech) with 100 mg/ml yeast tRNA. Twentyfive nanograms of the cDNA probe were radiolabelled with dCTP[a-32 P] (ICN) by random priming, and between 0.5 and 1 Â 10 6 cpm of the labelled probe was added per ml hybridization buffer and hybridized overnight at 661C. Membranes were washed to a stringency of 2 Â SSC, 0.1% SDS at 421C, exposed to X-ray films and stored at -801C until detection. To verify equal loading and integrity of RNA, all gels were stained with ethidium bromide. mRNA levels were normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 18S rRNA.
siRNA transfection
The siRNA duplexes for targeted silencing of DNMT1 were prepared by using the Silencer siRNA Construction Kit (Ambion). The target DNMT1-mRNA is encoded from exon 37 of the DNMT1 gene. The sequence of the siRNA is 5 0 -UGUGCUCGCUCCCAAGGCUUU-3 0 (sense strand) and 3 0 -UUACACGAGCGAGGGUUCCGA-5 0 (antisense strand). A Blast search of the rat genome database was carried out to ensure that the sequence would not target other gene transcripts. Briefly, 1 Â 10 5 cells were plated and grown in six-well plates 24 h before transfection, washed with 1 Â PBS, and 800 ml OptiMEM (Gibco) was added per well. For each well, 10 nM siRNA was mixed with 3 ml of Oligofectamine (Invitrogen, Carlsbad, CA, USA) in 40 ml of OptiMEM. The mixtures were incubated for 20 min at room temperature and then added to cells. Serum was added 4 h later to a final concentration of 10%. Transfection was repeated 24 h later, and 72 h after the second transfection, total RNA was collected for Northern blot analysis.
Bisulphite sequencing DNA was isolated by phenol/chloroform extraction. Following digestion of 500 ng DNA with EcoRV overnight, probes were denatured for 10 min at 951C, cooled on ice, and finally 50 ml of 2% LMP agarose (Sigma) prewarmed to 501C was added to keep the DNA in a denatured state. Then 750 ml of a 2.7 M sodium bisulphite solution (pH 5; Merck, Darmstadt, Germany) and 5 mM hydroquinone (Sigma) were overlaid with 750 ml of heavy mineral oil (Aldrich) and cooled on ice. A measure of 10 ml of the sample/agarose mixture was pipetted into the cold mineral oil layer to form agarose beads (Olek et al., 1996) . The solution was incubated for 3.5 h at 501C. After washing three times (1 ml) for 15 min with 1 Â TE Buffer (pH 8.0), the conversion reaction was completed by de-sulphonating twice for 15 min in 0.2 M NaOH. After repeated washing, 2-5 ml of the bisulphate-modified DNA was used as a template in each PCR reaction performed with the HotStartTaq Master Mix Kit (Qiagen, Hilden, Germany) using the following conditions: 951C for 15 min, 40 cycles of 1 min denaturation at 951C, 1 min annealing at primer-specific temperatures (Table 4 ) and 1 min of extension at 721C. The PCR reaction was terminated with 10 min of extension at 721C and cooled to 41C. Primers (Metabion, Martinsried, Germany) for amplification of bisulphate-modified DNA were designed with the assistance of the Oligo3 software and MethPrimer (Li and Dahiya, 2002) . PCR products were resolved on a 1-2% agarose gel, the specific band was excised and the PCR product was purified using the QIAquick Gel Extraction system (Qiagen) or Jetsorb (Genomed). The purified PCR products were cloned by the TOPO TA Cloning Kit (pCR2.1-TOPO Vector; Invitrogen, CA, USA) or the pGem-T Vector System I (Promega), and at least 12 clones were sequenced using the Sequiterm sequencing kit (Epicentre, Madison, WI, USA) by sequencing on a CEQ8000 (Beckman-Coulter) in each experiment or by using a commercial sequencing service (AGOWA, Berlin, Germany).
Abbreviations 5-Aza-CdR, 5-Aza-2-deoxycytidine; Thbs1, thrombospondin 1; Mmp2, matrix metalloproteinase 2; Ppicap, peptidylpropyl isomerase C-associated protein; Thbs1, thrombospondin 1; Timp2, tissue inhibitor of metalloproteinase 2.
